Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Jasonthehumbleon Jun 30, 2020 3:35pm

128 Views

Post# 31209513

RE:RE:RE:RE:RE:RE:RE:RE:second quarter - one day before annual meeting

I am going over some of the board of directors for Thera and some of them dont have much skin the game....they have a lot less stocks than Paul Lev who was just appointed the CEO.

For example, Sheila Frame only has 6k shares but was appointed back March 2019. Gary Littlejohn only has 11k shares appointed back October 2018. Dale Weil has 16k shares but appointed back May 2017....why do we have people on the board that does not have much skin in the game...why are they making decisions for the company when they dont have as much to lose?

I consider myself a little investor and I have like 20k shares at this point...which is only evquilvalent to $40,000USD.

Bullboard Posts

Nextech CEO provides company update on Amazon deal and more